ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Glucocorticoids and immune checkpoint inhibitors in glioblastoma.

Kelly, William J; Gilbert, Mark R*National Institutes of Health; NIH
Journal of Neuro-Oncology2021-1DOI: 10.1007/s11060-020-03439-2
6阅读
引用收藏
分享

摘要

PURPOSE: Immunotherapy, activation of the immune system to target tumor cells, represents a paradigm shift in the treatment of cancer. Immune checkpoint therapies, which target immunomodulatory molecules expressed on T-lymphocytes, have demonstrated improved survival in a variety of malignancies. However, benefit in glioblastoma, the most common and devastating malignant brain tumor, remains to be seen. With several recent clinical trials failing to show efficacy of immunotherapy, concerns have been raised regarding the impact of glucocorticoid use in this patient population that may impair the ability for immune checkpoint inhibitors to affect a response. METHODS: For this article we examined the mechanism by which immune checkpoint inhibitors activate, and glucocorticoids impair, T-lymphocyte function. RESULTS: In this context, we review the clinical data of immune checkpoint inhibitors in glioblastoma as well as the impact glucocorticoids have on immune checkpoint inhibitor efficacy. Finally, we highlight key questions that remain in the field, and the potential benefit of further research for central nervous system tumors. CONCLUSION: More information on the extent, character and duration of glucocorticoids on patients treated with PD-(L)1 will better inform both clinical management and novel therapeutic development of immunotherapy in patients with CNS malignancies.

学科与关键词

关键词
CNSCheckpointGlioblastomaGlucocorticoidsImmuneSteroids
相关
加载中…
  • Immune suppression in gliomas.
    Grabowski, Matthew M; Sankey, Eric W; Ryan, Katherine J; Chongsathidkiet, Pakawat; Lorrey, Selena J; Wilkinson, Daniel S; Fecci, Peter E*Journal of Neuro-Oncology, 2021, 151(1): 3-12.
  • Current Immunotherapies for Glioblastoma Multiforme
    Huang, Boyuan; Li, Xuesong; Li, Yuntao; Zhang, Jin; Zong, Zhitao*; Zhang, Hongbo*Frontiers in Immunology, 2021, 11: 603911.被引 63
  • The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
    Liu, Xudong; Zhao, Zihui; Dai, Wufei; Liao, Kuo; Sun, Qi; Chen, Dongjiang; Pan, Xingxin; Feng, Lishuang; Ding, Ying; Wei, Shiyou*Cancers, 2023, 15(17): 4308.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Neuro-Oncology
发表日期
2021-01
卷期
第 151 卷, 第 1 期
页码
13-20
DOI
10.1007/s11060-020-03439-2
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
PUBMED

作者

  • K

    Kelly, William J (第一作者)

    national institutes of health

  • G

    Gilbert, Mark R (通讯)

    national institutes of health

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417